- Home
- VRNA vs VERA Comparison
VRNA vs VERA Comparison
Compare VRNA & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- VERA
- Stock Information
- Founded
- VRNA 2005
- VERA 2016
- Country
- VRNA United Kingdom
- VERA United States
- Employees
- VRNA N/A
- VERA N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- VRNA Health Care
- VERA Health Care
- Exchange
- VRNA Nasdaq
- VERA Nasdaq
- Market Cap
- VRNA 3.2B
- VERA 2.8B
- IPO Year
- VRNA 2017
- VERA 2021
- Fundamental
- Price
- VRNA $43.06
- VERA $43.87
- Analyst Decision
- VRNA Strong Buy
- VERA Strong Buy
- Analyst Count
- VRNA 6
- VERA 9
- Target Price
- VRNA $43.83
- VERA $59.22
- AVG Volume (30 Days)
- VRNA 1.0M
- VERA 434.6K
- Earning Date
- VRNA 11-04-2024
- VERA 11-07-2024
- Dividend Yield
- VRNA N/A
- VERA N/A
- EPS Growth
- VRNA N/A
- VERA N/A
- EPS
- VRNA N/A
- VERA N/A
- Revenue
- VRNA $5,624,000.00
- VERA N/A
- Revenue This Year
- VRNA N/A
- VERA N/A
- Revenue Next Year
- VRNA $644.06
- VERA N/A
- P/E Ratio
- VRNA N/A
- VERA N/A
- Revenue Growth
- VRNA 1127.95
- VERA N/A
- 52 Week Low
- VRNA $11.39
- VERA $14.20
- 52 Week High
- VRNA $43.73
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- VRNA 61.99
- VERA 38.70
- Support Level
- VRNA $38.77
- VERA $43.13
- Resistance Level
- VRNA $43.73
- VERA $49.77
- Average True Range (ATR)
- VRNA 1.41
- VERA 1.97
- MACD
- VRNA 0.07
- VERA -0.74
- Stochastic Oscillator
- VRNA 60.80
- VERA 10.79
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.